We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+34.57%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$712M
AUM Growth
+$90.4M
Cap. Flow
+$220K
Cap. Flow %
0.03%
Top 10 Hldgs %
33.84%
Holding
126
New
27
Increased
25
Reduced
33
Closed
22

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$10.6M
2
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
3
HELP
Cybin Inc
HELP
+$9.73M
4
S icon
SentinelOne
S
+$8.81M
5
JSPR icon
Jasper Therapeutics
JSPR
+$7.71M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$15.3M
2
ATXS
Astria Therapeutics
ATXS
+$12.9M
3
TSEM icon
Tower Semiconductor
TSEM
+$10.9M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.61M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 65.19%
2 Technology 15.63%
3 Communication Services 2.68%
4 Consumer Discretionary 2.45%
5 Utilities 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$44.2M 6.21%
3,132,700
+1,848,700
+144% +$23.3M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$36.1M 5.07%
380,000
-120,000
-24% -$11.1M
TEVA icon
3
Teva Pharmaceuticals
TEVA
$40.8B
$26.7M 3.75%
1,889,700
-579,400
-23% -$7.3M
SNY icon
4
Sanofi
SNY
$103B
$24.3M 3.41%
499,515
– –
NICE icon
5
Nice
NICE
$5.79B
$22.4M 3.14%
85,881
+18,163
+27% +$4.12M
CYTK icon
6
Cytokinetics
CYTK
$10.5B
$19.7M 2.77%
281,671
+57,851
+26% +$4.47M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.69B
$19.3M 2.72%
812,964
+40,000
+5% +$892K
BBIO icon
8
BridgeBio Pharma
BBIO
$15.7B
$18.1M 2.55%
585,956
+303,810
+108% +$10.3M
BIIB icon
9
Biogen
BIIB
$30B
$15.2M 2.14%
70,646
+24,300
+52% +$5.69M
JSPR icon
10
Jasper Therapeutics
JSPR
$21M
$14.8M 2.08%
505,242
+433,936
+609% +$7.71M
CATX icon
11
Perspective Therapeutics
CATX
$332M
$14.8M 2.08%
1,244,362
+1,241,795
+48,375% +$10.6M
MRK icon
12
Merck
MRK
$322B
$13.7M 1.92%
103,600
-20,000
-16% -$2.47M
KURA icon
13
Kura Oncology
KURA
$800M
$13M 1.83%
610,826
-92,461
-13% -$1.8M
AZN icon
14
AstraZeneca
AZN
$263B
$12.9M 1.81%
95,030
+5,000
+6% +$662K
S icon
15
SentinelOne
S
$6.53B
$12.8M 1.8%
550,818
+337,400
+158% +$8.81M
JNJ icon
16
Johnson & Johnson
JNJ
$618B
$12.6M 1.77%
79,831
– –
META icon
17
Meta Platforms (Facebook)
META
$1.42T
$12.4M 1.74%
25,439
-8,864
-26% -$3.95M
CLDX icon
18
Celldex Therapeutics
CLDX
$2.99B
$11.6M 1.63%
276,996
-38,648
-12% -$1.59M
MSFT icon
19
Microsoft
MSFT
$3.45T
$11.6M 1.63%
27,548
+3,700
+16% +$1.5M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.45B
$11.1M 1.56%
238,544
+37,500
+19% +$1.77M
LLY icon
21
Eli Lilly
LLY
$1.02T
$11M 1.55%
14,190
– –
PRAX icon
22
Praxis Precision Medicines
PRAX
$8.58B
$10.8M 1.52%
177,139
-151,847
-46% -$6.81M
NVO
23
Novo Nordisk
NVO
$208B
$10.7M 1.5%
83,080
-10,000
-11% -$1.19M
HELP
24
Cybin Inc
HELP
$485M
$10.6M 1.49%
+673,195
New +$9.73M
INZY
25
DELISTED
Inozyme Pharma
INZY
$10.5M 1.48%
1,372,907
-190,000
-12% -$1.04M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sphera Funds Management held 126 positions worth $712M, up 15% from $621M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management's Q1 2024 filing shows 27 new, 25 increased, 33 reduced and 22 closed positions. Its largest new stake was Cybin Inc: 673,195 shares worth $10.6M. The largest sale was Nova, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2024 buy was Cybin Inc: 673,195 shares worth $10.6M.
  • Sphera Funds Management added most to Perspective Therapeutics in Q1 2024, an estimated $10.6M increase.
  • Sphera Funds Management's biggest Q1 2024 reduction was Nova, cutting an estimated $15.3M.
  • Sphera Funds Management fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $8.61M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $712M portfolio in Q1 2024.
  • Sphera Funds Management opened 27 new positions and closed 22 in Q1 2024.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $712M.

Based on Sphera Funds Management's 13F filing for Q1 2024, filed 15 May 2024.